Vericel Corp. (VCEL) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162426,
    "name": "Vericel Corp.",
    "stock_name": "Vericel Corp.",
    "full_name": "Vericel Corp.",
    "name_url": "stocks-analysis/vericel-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "36.79",
    "chg": -0.86,
    "chgp": "-2.28%",
    "dir": -1,
    "prev_price": "37.65",
    "mcapval": "1,676.29",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US92346J1088",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "978.05 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vericel-corp-1162426-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Complex Financial Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vericel-corp-sees-valuation-grade-shift-from-fair-to-expensive-amid-high-pe-ratio-3686287",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VericelCorp_valuationdot_3686287.png",
        "date": "2025-11-10 16:04:34",
        "description": "Vericel Corp., a small-cap biotechnology firm, has experienced a valuation adjustment, showcasing a notably high P/E ratio of 732 and a Price to Book Value of 7.38. Its performance metrics indicate challenges in generating returns, contrasting sharply with peers like Madrigal Pharmaceuticals and Cytokinetics."
      },
      {
        "title": "Vericel Corp. Experiences Valuation Adjustment Amidst Unique Market Position and Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vericel-corp-sees-valuation-grade-upgrade-from-fair-to-very-attractive-3667133",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/VericelCorp_valuationdot_3667133.png",
        "date": "2025-11-03 16:00:43",
        "description": "Vericel Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has experienced a valuation adjustment, reflected in its high P/E ratio of 732 and price-to-book value of 7.38. Despite a year-to-date return of -36.15%, its performance metrics indicate potential areas for profitability improvement compared to peers."
      },
      {
        "title": "Is Vericel Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vericel-corp-overvalued-or-undervalued-3637323",
        "imagepath": "",
        "date": "2025-10-21 12:00:00",
        "description": "As of 17 October 2025, the valuation grade for Vericel Corp. has moved from attractive to fair, indicating a shift in its perceived value. Based on the current metrics, Vericel appears to be overvalued, particularly highlighted by its P/E ratio of 732, which is significantly higher than the industry average, and an EV to EBITDA of 517.61, suggesting an inflated valuation relative to earnings. Additionally, the PEG ratio stands at 1.35, which, while not excessively high, does not compensate for the other concerning ratios.\n\nIn comparison to its peers, Vericel's P/E ratio of 732 starkly contrasts with Harmony Biosciences Holdings, which has a P/E of 11.40, and Amphastar Pharmaceuticals at 11.49, both of which are in a more attractive valuation range. Furthermore, Vericel's recent stock performance shows a 1-week return of 10.89%, significantly outperforming the S&P 500's 1.70% return, but it has underperforme..."
      },
      {
        "title": "Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Complex Financial Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vericel-corp-sees-valuation-grade-downgrade-from-attractive-to-fair-amid-high-pe-ratio-3640999",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VericelCorp_valuationdot_3640999.png",
        "date": "2025-10-20 17:07:26",
        "description": "Vericel Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment, showcasing a notably high P/E ratio of 732 and a price-to-book value of 7.38. Its performance metrics indicate challenges in generating returns, contrasting sharply with peers in the industry."
      },
      {
        "title": "Is Vericel Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vericel-corp-overvalued-or-undervalued-3631731",
        "imagepath": "",
        "date": "2025-10-19 11:55:36",
        "description": "As of 17 October 2025, the valuation grade for Vericel Corp. has moved from attractive to fair, indicating a shift in its perceived value. Based on the current metrics, the company appears to be overvalued, with a P/E ratio of 732, a Price to Book Value of 7.38, and an EV to EBITDA of 517.61. In comparison, its peer, Harmony Biosciences Holdings, Inc. has a P/E of 11.40, while Amphastar Pharmaceuticals, Inc. has a P/E of 11.49, highlighting a significant disparity in valuation.\n\nThe recent stock performance shows that Vericel Corp. has underperformed relative to the S&P 500, particularly over the year-to-date period, where it has returned -35.68% compared to the S&P 500's 13.30%. This trend reinforces the notion that the stock may be overvalued given its high valuation ratios and poor recent performance...."
      },
      {
        "title": "Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Unique Financial Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vericel-corp-sees-valuation-grade-upgrade-from-fair-to-very-attractive-3595451",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VericelCorp_valuationdot_3595451.png",
        "date": "2025-10-06 16:08:47",
        "description": "Vericel Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has undergone a valuation adjustment reflecting its financial metrics and market position. With a notably high P/E ratio and distinct financial ratios, the company presents a unique profile amid challenges in the industry, raising questions about its profitability and efficiency."
      },
      {
        "title": "Is Vericel Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-vericel-corp-overvalued-or-undervalued-3591336",
        "imagepath": "",
        "date": "2025-10-05 11:13:19",
        "description": "As of 3 October 2025, Vericel Corp. has moved from a fair to a very attractive valuation grade. The company appears to be undervalued, particularly when considering its P/E ratio of 732, which is significantly higher than the peer average of 235.86, and an EV to EBITDA ratio of 517.61, indicating potential overvaluation relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the PEG ratio stands at 1.35, suggesting that the stock may be undervalued in relation to its growth rate.\n\nIn comparison to its peers, Vericel Corp. has a much higher P/E ratio than Madrigal Pharmaceuticals, which is at -35.88, and Cytokinetics, which is at -10.74, both of which are considered risky investments. Despite the attractive valuation grade, Vericel has underperformed against the S&P 500 year-to-date, with a return of -40.92% compared to the index's 14.18%. However, over the last three years..."
      },
      {
        "title": "Vericel Corp. Experiences Valuation Adjustment Amid Unique Market Dynamics and Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vericel-corp-sees-valuation-grade-upgrade-from-fair-to-very-attractive-3579916",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/VericelCorp_valuationdot_3579916.png",
        "date": "2025-09-29 16:09:30",
        "description": "Vericel Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has experienced a valuation adjustment, reflected in its high P/E ratio of 732 and a price-to-book value of 7.38. Despite a year-to-date decline, the company shows a notable five-year increase, indicating unique market dynamics and volatility."
      },
      {
        "title": "Vericel Corp. Hits New 52-Week Low at $29.24 Amidst Declining Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vericel-corp-hits-new-52-week-low-at-2924-amidst-declining-performance-3574451",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/VericelCorp_priceRelatedfactors_3574451.png",
        "date": "2025-09-26 15:04:19",
        "description": "Vericel Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 1,676 million, has a high P/E ratio and faces challenges in profitability, evidenced by a recent net loss."
      }
    ],
    "total": 21,
    "sid": "1162426",
    "stock_news_url": "https://www.marketsmojo.com/news/vericel-corp-1162426"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Complex Financial Metrics

2025-11-10 16:04:34

Vericel Corp., a small-cap biotechnology firm, has experienced a valuation adjustment, showcasing a notably high P/E ratio of 732 and a Price to Book Value of 7.38. Its performance metrics indicate challenges in generating returns, contrasting sharply with peers like Madrigal Pharmaceuticals and Cytokinetics.

Vericel Corp. Experiences Valuation Adjustment Amidst Unique Market Position and Performance Metrics

2025-11-03 16:00:43

Vericel Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has experienced a valuation adjustment, reflected in its high P/E ratio of 732 and price-to-book value of 7.38. Despite a year-to-date return of -36.15%, its performance metrics indicate potential areas for profitability improvement compared to peers.

Is Vericel Corp. overvalued or undervalued?

2025-10-21 12:00:00

As of 17 October 2025, the valuation grade for Vericel Corp. has moved from attractive to fair, indicating a shift in its perceived value. Based on the current metrics, Vericel appears to be overvalued, particularly highlighted by its P/E ratio of 732, which is significantly higher than the industry average, and an EV to EBITDA of 517.61, suggesting an inflated valuation relative to earnings. Additionally, the PEG ratio stands at 1.35, which, while not excessively high, does not compensate for the other concerning ratios. In comparison to its peers, Vericel's P/E ratio of 732 starkly contrasts with Harmony Biosciences Holdings, which has a P/E of 11.40, and Amphastar Pharmaceuticals at 11.49, both of which are in a more attractive valuation range. Furthermore, Vericel's recent stock performance shows a 1-week return of 10.89%, significantly outperforming the S&P 500's 1.70% return, but it has underperforme...

Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Complex Financial Landscape

2025-10-20 17:07:26

Vericel Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment, showcasing a notably high P/E ratio of 732 and a price-to-book value of 7.38. Its performance metrics indicate challenges in generating returns, contrasting sharply with peers in the industry.

Is Vericel Corp. overvalued or undervalued?

2025-10-19 11:55:36

As of 17 October 2025, the valuation grade for Vericel Corp. has moved from attractive to fair, indicating a shift in its perceived value. Based on the current metrics, the company appears to be overvalued, with a P/E ratio of 732, a Price to Book Value of 7.38, and an EV to EBITDA of 517.61. In comparison, its peer, Harmony Biosciences Holdings, Inc. has a P/E of 11.40, while Amphastar Pharmaceuticals, Inc. has a P/E of 11.49, highlighting a significant disparity in valuation. The recent stock performance shows that Vericel Corp. has underperformed relative to the S&P 500, particularly over the year-to-date period, where it has returned -35.68% compared to the S&P 500's 13.30%. This trend reinforces the notion that the stock may be overvalued given its high valuation ratios and poor recent performance....

Vericel Corp. Experiences Revision in Its Stock Evaluation Amid Unique Financial Metrics

2025-10-06 16:08:47

Vericel Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has undergone a valuation adjustment reflecting its financial metrics and market position. With a notably high P/E ratio and distinct financial ratios, the company presents a unique profile amid challenges in the industry, raising questions about its profitability and efficiency.

Is Vericel Corp. overvalued or undervalued?

2025-10-05 11:13:19

As of 3 October 2025, Vericel Corp. has moved from a fair to a very attractive valuation grade. The company appears to be undervalued, particularly when considering its P/E ratio of 732, which is significantly higher than the peer average of 235.86, and an EV to EBITDA ratio of 517.61, indicating potential overvaluation relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the PEG ratio stands at 1.35, suggesting that the stock may be undervalued in relation to its growth rate. In comparison to its peers, Vericel Corp. has a much higher P/E ratio than Madrigal Pharmaceuticals, which is at -35.88, and Cytokinetics, which is at -10.74, both of which are considered risky investments. Despite the attractive valuation grade, Vericel has underperformed against the S&P 500 year-to-date, with a return of -40.92% compared to the index's 14.18%. However, over the last three years...

Vericel Corp. Experiences Valuation Adjustment Amid Unique Market Dynamics and Performance Metrics

2025-09-29 16:09:30

Vericel Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has experienced a valuation adjustment, reflected in its high P/E ratio of 732 and a price-to-book value of 7.38. Despite a year-to-date decline, the company shows a notable five-year increase, indicating unique market dynamics and volatility.

Vericel Corp. Hits New 52-Week Low at $29.24 Amidst Declining Performance

2025-09-26 15:04:19

Vericel Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 1,676 million, has a high P/E ratio and faces challenges in profitability, evidenced by a recent net loss.

View All News